0
On 15 January 2026, the US Food and Drug Administration (FDA) approved the first biosimilar of the year, Accord Biopharma’s Filkri (filgrastim-laha), a biosimilar to Amgen’s Neupogen (fil...
More >- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- FDA approves filgrastim biosimilar Filkri
- EC approves golimumab biosimilar Gotenfia and ranibizumab biosimilar Ranluspec
- EMA recommends approval for teriparatide biosimilar Zandoriah
- FDA approves third interchangeable ranibizumab biosimilar Nufymco
Research
- OECD study finds no direct link between advertising rules and biosimilar uptake
- Reaching ESG goals in pharmaceutical development
- What is the future for the US biosimilar interchangeability designation
- Biosimilar clinical efficacy studies: are they still necessary?
- MORE EDITORIAL SECTIONS
- Search
